(in thousands, except per share data)

	Fiscal 2013 Quarter Ended

	March 31			June 30			September 30			December 31
Revenues(1)	$	71,077		$	101,675		$	85,123			97,072
Net loss	$	(15,669	)	$	(2,571	)	$	(22,037	)		(42,870	)
Basic and diluted net loss per share	$	(0.12	)	$	(0.02	)	$	(0.14	)		(0.26	)
Shares used in computation of basic and diluted net loss per share		134,345			142,284			155,067			161,914

	Fiscal 2012 Quarter Ended

	March 31			June 30		September 30			December 31
Revenues(2)	$	36,179		$	86,542	$	60,492		$	113,845
Net income (loss)	$	(45,426	)	$	4,037	$	(21,710	)	$	18,779
Basic net income (loss) per share	$	(0.36	)	$	0.03	$	(0.17	)	$	0.14
Diluted net income (loss) per share	$	(0.36	)	$	0.03	$	(0.17	)	$	0.14
Shares used in computation of basic net income (loss) per share		127,203			129,224		130,851			131,711
Shares used in computation of diluted net income (loss) per share		127,203			137,969		130,851			139,118

(1): The quarters ended March 31, 2013, June 30, 2013, September 30, 2013 and December 31, 2013 include $48.3 million, $54.1 million, $60.2 million and $72.8 million, respectively of product revenues, net, relating to JAKAFI. The quarters ended March 31, 2013, June 30, 2013, September 30, 2013 and December 31, 2013 include $5.9 million, $5.8 million, $8.2 million and $8.4 million, respectively of product royalty revenues related to the sale of JAKAVI outside the United States. In November 2009 and December 2009, we entered into collaborative research and license agreements with Novartis and Lilly, respectively. The quarters ended March 31, 2013, June 30, 2013, September 30, 2013 and December 31, 2013 include $16.7 million, $41.7 million, $16.7 million and $15.8 million, respectively of contract revenues relating to these agreements.
(2): The quarters ended March 31, 2012, June 30, 2012, September 30, 2012 and December 31, 2012 include $19.3 million, $29.7 million, $43.7 million and $43.3 million, respectively of product revenues, net, relating to JAKAFI. The quarter ended December 31, 2012 includes $3.7 million of product royalty revenues related to the sale of JAKAVI outside the United States. In November 2009 and December 2009, we entered into collaborative research and license agreements with Novartis and Lilly, respectively. The quarters ended March 31, 2012, June 30, 2012, September 30, 2012 and December 31, 2012 include $16.7 million, $56.7 million, $16.7 million and $66.7 million, respectively of contract revenues relating to these agreements.